Methods for assessing inverse publication bias of adverse events.

Adverse event Funnel plot Inverse publication bias Publication bias Regression test

Journal

Contemporary clinical trials
ISSN: 1559-2030
Titre abrégé: Contemp Clin Trials
Pays: United States
ID NLM: 101242342

Informations de publication

Date de publication:
29 Jul 2024
Historique:
received: 06 12 2023
revised: 06 06 2024
accepted: 27 07 2024
medline: 1 8 2024
pubmed: 1 8 2024
entrez: 31 7 2024
Statut: aheadofprint

Résumé

In medical research, publication bias (PB) poses great challenges to the conclusions from systematic reviews and meta-analyses. The majority of efforts in methodological research related to classic PB have focused on examining the potential suppression of studies reporting effects close to the null or statistically non-significant results. Such suppression is common, particularly when the study outcome concerns the effectiveness of a new intervention. On the other hand, attention has recently been drawn to the so-called inverse publication bias (IPB) within the evidence synthesis community. It can occur when assessing adverse events because researchers may favor evidence showing a similar safety profile regarding an adverse event between a new intervention and a control group. In comparison to the classic PB, IPB is much less recognized in the current literature; methods designed for classic PB may be inaccurately applied to address IPB, potentially leading to entirely incorrect conclusions. This article aims to provide a collection of accessible methods to assess IPB for adverse events. Specifically, we discuss the relevance and differences between classic PB and IPB. We also demonstrate visual assessment through contour-enhanced funnel plots tailored to adverse events and popular quantitative methods, including Egger's regression test, Peters' regression test, and the trim-and-fill method for such cases. Three real-world examples are presented to illustrate the bias in various scenarios, and the implementations are illustrated with statistical code. We hope this article offers valuable insights for evaluating IPB in future systematic reviews of adverse events.

Identifiants

pubmed: 39084407
pii: S1551-7144(24)00229-5
doi: 10.1016/j.cct.2024.107646
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107646

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Xing Xing (X)

Department of Biostatistics, Johns Hopkins University, Maryland, MD, USA.

Chang Xu (C)

Clinical Transformation Center, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China.

Fahad M Al Amer (FM)

Department of Mathematics, College of Science and Arts, Najran University, Najran, Saudi Arabia.

Linyu Shi (L)

AbbVie Inc, North Chicago, IL, USA.

Jianan Zhu (J)

Department of Biostatistics, School of Global Public Health, New York University, New York, NY, USA.

Lifeng Lin (L)

Department of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA. Electronic address: lifenglin@arizona.edu.

Classifications MeSH